NOOTROPIC COMPOSITION BASED ON POLYPEPTIDE COMPLEXES ISOLATED FROM NEURONS AND GLIAL CELLS OBTAINED BY DIRECTED DIFFERENTIATION OF INDUCED HUMAN PLURIPOTENT STEM CELLS Russian patent published in 2019 - IPC A61K35/30 A61K38/17 A61P25/28 

FIELD: biotechnology.

SUBSTANCE: invention represents a nootropic protein-peptide composition based on polypeptide complexes recovered from neurons and glial cells obtained by directed differentiation induced pluripotent stem cells human being, characterized in that it contains proteins and polypeptides with molecular weight from 0.5 to 100 kDa, of which 75 % have molecular weight in range of 10 to 90 kDa, content of cerebral neurotrophic factor (BDNF) of not less than 50 pg/ml and glial neurotrophic factor (GDNF) of not less than 40 pg/ml, total protein weight is not less than 20 mg/ml of preparation, wherein cell culture of induced pluripotent stem cells, from which composition is produced, shows expression of genes specific for IPSC OCT4, SOX2, NANOG, FOXD3, HESX1, SALL4, as well as for neural cells DARPP-32, PAX6, FOXP2, NCAM1, ENO2, Nestin, TUBB3, HTT and synaptic transporter GABA GAT1. Use of human cell cultures enables to obtain a protein-peptide composition which will include not only small peptides but also full-length protein neuronal growth and differentiation factors. Effectiveness of such factors is certainly higher than that of short peptides, and immunogenicity is absent.

EFFECT: use IPSC as a protein-peptide composition production source, it is possible to solve the problem of donor material deficiency and ethical issues occurring when using embryonic material and human embryonic stem cell cultures for similar purposes.

1 cl, 4 ex, 3 dwg